دورية أكاديمية
أعرض في EDS

Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia.

التفاصيل البيبلوغرافية
العنوان: Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia.
المؤلفون: Pang Y; Department of Haematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC, USA. Electronic address: yifan.pang@atriumhealth.org., Holtzman NG; Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
المصدر: Best practice & research. Clinical haematology [Best Pract Res Clin Haematol] 2023 Jun; Vol. 36 (2), pp. 101475. Date of Electronic Publication: 2023 May 11.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101120659 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1924 (Electronic) Linking ISSN: 15216926 NLM ISO Abbreviation: Best Pract Res Clin Haematol Subsets: MEDLINE
أسماء مطبوعة: Publication: Amsterdam : Elsevier
Original Publication: London, U.K. : Baillière Tindall, c2001-
مواضيع طبية MeSH: Graft vs Host Disease*/prevention & control , Graft vs Host Disease*/etiology , Hematopoietic Stem Cell Transplantation*/adverse effects , Leukemia, Myeloid, Acute*/therapy, Humans ; Graft vs Leukemia Effect ; Neoplasm Recurrence, Local/complications ; Transplantation, Homologous/adverse effects
مستخلص: Allogeneic haematopoietic stem cell transplantation (HSCT) remains the only potential cure for intermediate to high-risk acute myeloid leukaemia (AML). The therapeutic effect of HSCT is largely dependent on the powerful donor-derived immune response against recipient leukaemia cells, known as graft-versus-leukaemia effect (GvL). However, the donor-derived immune system can also cause acute or chronic damage to normal recipient organs and tissues, in a process known as graft-versus-host disease (GvHD). GvHD is a leading cause of non-relapse mortality in HSCT recipients. There are many similarities and cross talk between the immune pathways of GvL and GvHD. Studies have demonstrated that both processes require the presence of mismatched alloantigens between the donor and recipient, and activation of immune responses centered around donor T-cells, which can be further modulated by various recipient or donor factors. Dissecting GvL from GvHD to achieve more effective GvHD prevention and enhanced GvL has been the holy grail of HSCT research. In this review, we focused on the key factors that contribute to the immune responses of GvL and GvHD, the effect on GvL with different GvHD prophylactic strategies, and the potential impact of various AML relapse prevention therapy or treatments on GvHD.
Competing Interests: Declaration of competing interest The authors declare no conflicts of interest.
(Copyright © 2023 Elsevier Ltd. All rights reserved.)
References: Br J Haematol. 2019 Mar;184(5):782-787. (PMID: 30467839)
Ann Hematol. 2021 Sep;100(9):2339-2350. (PMID: 33796897)
Leukemia. 2016 Oct;30(10):2102-2106. (PMID: 27211264)
Transplantation. 1987 Sep;44(3):335-9. (PMID: 2957834)
Blood Adv. 2022 Nov 22;6(22):5857-5865. (PMID: 36150050)
Cancer Sci. 2021 Sep;112(9):3636-3644. (PMID: 34185931)
Blood. 2016 Aug 11;128(6):794-804. (PMID: 27338097)
Front Immunol. 2019 Nov 29;10:2668. (PMID: 31849930)
N Engl J Med. 1998 Oct 22;339(17):1177-85. (PMID: 9780337)
Front Oncol. 2022 Jan 03;11:793274. (PMID: 35047405)
Front Immunol. 2022 Jun 16;13:915837. (PMID: 35784326)
Biol Blood Marrow Transplant. 2013 Jun;19(6):949-57. (PMID: 23523892)
Lancet Haematol. 2019 Feb;6(2):e89-e99. (PMID: 30709437)
J Clin Oncol. 2005 Aug 1;23(22):5074-87. (PMID: 16051954)
Biol Blood Marrow Transplant. 2015 Jun;21(6):959-70. (PMID: 25482864)
Blood Cancer J. 2019 Nov 18;9(12):88. (PMID: 31740656)
Bone Marrow Transplant. 2022 Aug;57(8):1217-1239. (PMID: 35589997)
Cancer. 2020 May 15;126(10):2193-2205. (PMID: 32125707)
Nat Med. 2011 Nov 29;18(1):135-42. (PMID: 22127134)
J Clin Oncol. 2022 Feb 1;40(4):356-368. (PMID: 34855460)
Blood. 2002 Nov 1;100(9):3108-14. (PMID: 12384406)
J Clin Oncol. 2022 Jan 10;40(2):189-201. (PMID: 34793200)
Lancet Oncol. 2009 Sep;10(9):855-64. (PMID: 19695955)
J Clin Oncol. 2019 Feb 10;37(5):375-385. (PMID: 30403573)
Haematologica. 2017 Feb;102(2):391-400. (PMID: 27846611)
Blood Adv. 2021 Oct 26;5(20):4278-4284. (PMID: 34521116)
PLoS One. 2011;6(8):e22523. (PMID: 21850230)
J Immunol. 2002 Dec 15;169(12):7111-8. (PMID: 12471148)
Bone Marrow Transplant. 2023 Apr 25;:. (PMID: 37185614)
Blood. 2023 Mar 23;141(12):1389-1401. (PMID: 36399701)
Leukemia. 2020 Dec;34(12):3420-3425. (PMID: 32393842)
J Clin Oncol. 2011 Jun 1;29(16):2230-9. (PMID: 21464398)
Cancer Gene Ther. 2020 Feb;27(1-2):1-14. (PMID: 31292516)
Front Immunol. 2020 Aug 20;11:1804. (PMID: 32973756)
J Clin Oncol. 2017 Dec 20;35(36):4003-4011. (PMID: 29040031)
Cytotherapy. 2022 Mar;24(3):311-319. (PMID: 34711501)
Blood Adv. 2021 Mar 9;5(5):1425-1436. (PMID: 33666654)
Transplant Cell Ther. 2022 Apr;28(4):204.e1-204.e10. (PMID: 35108627)
Annu Rev Immunol. 2021 Apr 26;39:19-49. (PMID: 33428454)
Nat Commun. 2022 May 9;13(1):2522. (PMID: 35534496)
Am J Pathol. 1978 Jun;91(3):545-70. (PMID: 26221)
Biol Blood Marrow Transplant. 2004 Oct;10(10):669-80. (PMID: 15389433)
J Hematol Oncol. 2020 May 6;13(1):46. (PMID: 32375860)
Eur J Haematol. 1993 May;50(5):269-74. (PMID: 8319789)
Bone Marrow Transplant. 2006 Aug;38(4):305-10. (PMID: 16819438)
Blood. 2020 Jul 2;136(1):130-136. (PMID: 32430495)
Blood Adv. 2018 Aug 28;2(16):2052-2062. (PMID: 30115642)
J Hematol Oncol. 2015 Feb 06;8:4. (PMID: 25652604)
Blood. 2017 Nov 23;130(21):2243-2250. (PMID: 28924018)
Nat Med. 2019 Apr;25(4):603-611. (PMID: 30911134)
Biol Blood Marrow Transplant. 2016 Nov;22(11):2065-2076. (PMID: 27530969)
Biol Blood Marrow Transplant. 1999;5(4):222-30. (PMID: 10465102)
Blood. 2007 Aug 1;110(3):1064-72. (PMID: 17449800)
Acta Derm Venereol. 2021 Jan 20;101(1):adv00374. (PMID: 32812057)
Biol Blood Marrow Transplant. 2017 May;23(5):820-829. (PMID: 28192251)
Blood. 2022 Mar 17;139(11):1670-1683. (PMID: 34871371)
EJHaem. 2020 May 26;1(1):286-292. (PMID: 35847727)
Blood. 1997 Oct 15;90(8):3204-13. (PMID: 9376604)
Hematol Oncol Stem Cell Ther. 2023 Jan 12;16(1):52-60. (PMID: 36634281)
Leuk Lymphoma. 2013 Jun;54(6):1228-34. (PMID: 23082952)
J Clin Oncol. 2022 Apr 10;40(11):1174-1185. (PMID: 35007144)
J Int Med Res. 2020 Jun;48(6):300060520925693. (PMID: 32527171)
Blood. 2000 Jan 1;95(1):352-9. (PMID: 10607724)
Blood. 2016 Feb 25;127(8):1044-51. (PMID: 26563133)
Blood. 2015 Feb 12;125(7):1189-97. (PMID: 25519752)
Blood. 1991 Oct 15;78(8):2120-30. (PMID: 1912589)
Ann Hematol. 2021 Apr;100(4):959-968. (PMID: 33191481)
Blood. 2007 Oct 1;110(7):2761-3. (PMID: 17579184)
Leukemia. 2022 Jan;36(1):257-262. (PMID: 34135465)
J Cancer. 2013;4(1):25-35. (PMID: 23386902)
Haematologica. 2022 May 01;107(5):1045-1053. (PMID: 34382386)
J Hematol Oncol. 2020 Dec 7;13(1):167. (PMID: 33287858)
Biol Blood Marrow Transplant. 1999;5(3):133-43. (PMID: 10392959)
Cancer Res. 2005 Nov 1;65(21):9735-40. (PMID: 16266994)
Blood. 2001 Dec 1;98(12):3192-204. (PMID: 11719354)
Biol Blood Marrow Transplant. 2015 Aug;21(8):1373-83. (PMID: 25977230)
Yonsei Med J. 2007 Feb 28;48(1):11-23. (PMID: 17326240)
Biol Blood Marrow Transplant. 2013 Feb;19(2):274-82. (PMID: 23022467)
Biol Blood Marrow Transplant. 2011 Sep;17(9):1343-51. (PMID: 21320619)
Blood. 1989 Apr;73(5):1340-50. (PMID: 2649174)
Clin Immunol. 2021 Sep;230:108823. (PMID: 34400321)
Front Immunol. 2017 Feb 10;8:109. (PMID: 28239380)
Ann Hematol. 2013 Apr;92(4):549-50. (PMID: 23111661)
Sci Transl Med. 2012 Jul 25;4(144):144ra101. (PMID: 22837536)
Bone Marrow Transplant. 2023 Apr 12;:. (PMID: 37045942)
N Engl J Med. 1979 May 10;300(19):1068-73. (PMID: 34792)
Biol Blood Marrow Transplant. 2015 Mar;21(3):454-9. (PMID: 25460355)
N Engl J Med. 2016 Jan 7;374(1):43-53. (PMID: 26735993)
J Immunol. 2012 Apr 15;188(8):3804-11. (PMID: 22422880)
Biol Blood Marrow Transplant. 2009 Feb;15(2):257-65. (PMID: 19167686)
Bone Marrow Transplant. 2022 Mar;57(3):384-390. (PMID: 35022535)
Bone Marrow Transplant. 2016 May;51(5):663-7. (PMID: 26437060)
Blood. 2022 Jan 27;139(4):608-623. (PMID: 34657151)
Blood. 2000 Jun 15;95(12):3996-4003. (PMID: 10845940)
Exp Hematol Oncol. 2022 Mar 2;11(1):11. (PMID: 35236415)
J Clin Invest. 2022 Jun 1;132(11):. (PMID: 35349491)
Front Immunol. 2022 Aug 29;13:971709. (PMID: 36105821)
Exp Hematol. 2016 Aug;44(8):674-88. (PMID: 27235758)
JCI Insight. 2022 Apr 8;7(7):. (PMID: 35239511)
Front Immunol. 2017 Apr 25;8:465. (PMID: 28487696)
Cytotherapy. 2022 Oct;24(10):1013-1025. (PMID: 35729020)
Bone Marrow Transplant. 1991 Feb;7(2):113-9. (PMID: 2049554)
J Exp Med. 1978 Dec 1;148(6):1687-98. (PMID: 363972)
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2742-7. (PMID: 12601144)
Front Immunol. 2020 May 12;11:699. (PMID: 32477328)
Front Immunol. 2022 Feb 15;13:796349. (PMID: 35242129)
Science. 2002 Mar 15;295(5562):2097-100. (PMID: 11896281)
Exp Hematol. 2017 Apr;48:1-11. (PMID: 28027963)
Cytotherapy. 1999;1(1):7-19. (PMID: 19746645)
Blood. 2012 Apr 19;119(16):3844-53. (PMID: 22101894)
Science. 1999 Jul 16;285(5426):412-5. (PMID: 10411505)
J Exp Med. 1982 Mar 1;155(3):872-83. (PMID: 6977610)
Biol Blood Marrow Transplant. 2015 Jan;21(1):130-6. (PMID: 25445640)
Nat Rev Cancer. 2004 May;4(5):371-80. (PMID: 15122208)
J Clin Invest. 2003 Dec;112(12):1880-6. (PMID: 14679183)
Blood. 2018 Mar 8;131(10):1063-1072. (PMID: 29358176)
Biol Blood Marrow Transplant. 2014 May;20(5):696-704. (PMID: 24525278)
Blood. 2007 Apr 1;109(7):3115-23. (PMID: 17148592)
Immunity. 2012 Aug 24;37(2):339-50. (PMID: 22921121)
Clin Cancer Res. 2015 May 1;21(9):2020-8. (PMID: 25348512)
J Immunol. 2002 Oct 15;169(8):4253-61. (PMID: 12370356)
EClinicalMedicine. 2021 Aug 25;40:101093. (PMID: 34746714)
Cancer Manag Res. 2021 Sep 24;13:7411-7427. (PMID: 34594134)
Front Immunol. 2021 Jun 18;12:697854. (PMID: 34220860)
Lancet Oncol. 2020 Sep;21(9):1201-1212. (PMID: 32791048)
Transplant Cell Ther. 2021 Oct;27(10):841-850. (PMID: 34118468)
Biol Blood Marrow Transplant. 2016 Jul;22(7):1290-1298. (PMID: 27090958)
Transplantation. 2009 Feb 27;87(4):473-81. (PMID: 19307782)
Biol Blood Marrow Transplant. 2017 Feb;23(2):211-234. (PMID: 27713092)
Front Immunol. 2021 May 03;12:659595. (PMID: 34012445)
J Clin Oncol. 2007 Nov 1;25(31):4938-45. (PMID: 17909197)
Blood. 1965 Feb;25:179-96. (PMID: 14267694)
J Clin Invest. 2019 May 1;129(5):1808-1817. (PMID: 31042160)
Nat Rev Immunol. 2007 May;7(5):340-52. (PMID: 17438575)
Bone Marrow Transplant. 2008 Feb;41(4):377-83. (PMID: 17982494)
Exp Hematol. 2008 Dec;36(12):1750-9. (PMID: 18809241)
Blood. 2013 Mar 7;121(10):1886-95. (PMID: 23303823)
J Clin Oncol. 2020 Sep 10;38(26):2993-3002. (PMID: 32673171)
Transplant Cell Ther. 2021 Aug;27(8):662.e1-662.e9. (PMID: 33901720)
BMC Bioinformatics. 2017 Jul 11;18(1):334. (PMID: 28697761)
Front Immunol. 2016 Dec 22;7:595. (PMID: 28066411)
Bone Marrow Res. 2012;2012:257086. (PMID: 23193478)
Bone Marrow Transplant. 2019 Apr;54(4):620-624. (PMID: 30287936)
Front Immunol. 2021 Jul 06;12:688066. (PMID: 34295334)
Blood. 2010 May 27;115(21):4293-301. (PMID: 20233969)
Leukemia. 2007 Jul;21(7):1387-94. (PMID: 17410187)
Bone Marrow Transplant. 2022 Feb;57(2):215-223. (PMID: 34750562)
Haematologica. 2022 May 01;107(5):1054-1063. (PMID: 34162176)
Bone Marrow Transplant. 2018 Jun;53(6):800-803. (PMID: 29535380)
J Clin Oncol. 2020 Dec 20;38(36):4249-4259. (PMID: 33108244)
J Hematol Oncol. 2015 Jun 26;8:78. (PMID: 26113077)
Blood. 2016 Jun 16;127(24):2963-70. (PMID: 27030390)
Haematologica. 2018 Aug;103(8):1317-1328. (PMID: 29748438)
Bone Marrow Transplant. 2007 Jun;39(12):751-7. (PMID: 17450185)
Blood. 1995 Aug 15;86(4):1261-8. (PMID: 7632930)
Blood Adv. 2020 Nov 10;4(21):5580-5588. (PMID: 33170934)
Leukemia. 2013 Sep;27(9):1910-3. (PMID: 23519388)
Biol Blood Marrow Transplant. 2020 Mar;26(3):438-444. (PMID: 31756535)
J Immunol. 2007 Nov 15;179(10):6547-54. (PMID: 17982043)
Sci Transl Med. 2013 Apr 3;5(179):179ra43. (PMID: 23552371)
J Clin Oncol. 2016 Sep 10;34(26):3141-9. (PMID: 27269951)
Blood. 2020 Apr 30;135(18):1548-1559. (PMID: 32181816)
Science. 1981 Sep 25;213(4515):1469-74. (PMID: 6792704)
Blood Adv. 2019 Dec 10;3(23):4081-4094. (PMID: 31821459)
J Immunol. 2004 Nov 1;173(9):5467-75. (PMID: 15494494)
Nat Med. 2004 Sep;10(9):987-92. (PMID: 15286785)
Biol Blood Marrow Transplant. 2016 Feb;22(2):385-390. (PMID: 26363443)
Front Immunol. 2021 Oct 05;12:761448. (PMID: 34675938)
Biol Blood Marrow Transplant. 2015 Feb;21(2):266-74. (PMID: 25445023)
Sci Transl Med. 2014 Jul 2;6(243):243ra87. (PMID: 24990882)
Biol Blood Marrow Transplant. 2004 Aug;10(8):540-51. (PMID: 15282532)
Bone Marrow Transplant. 2013 Mar;48(3):433-8. (PMID: 22941380)
Blood Adv. 2019 Nov 12;3(21):3436-3448. (PMID: 31714966)
Bone Marrow Transplant. 2021 Apr;56(4):956-959. (PMID: 33128029)
Hum Immunol. 1990 Oct;29(2):79-91. (PMID: 2249952)
Clin Transplant. 2012 Jul-Aug;26(4):635-43. (PMID: 22515260)
Br Med J. 1956 Sep 15;2(4993):626-7. (PMID: 13356034)
J Clin Oncol. 2013 Jul 1;31(19):2437-49. (PMID: 23715573)
Blood. 2015 Jun 18;125(25):3956-62. (PMID: 25940714)
Transplant Cell Ther. 2023 Mar;29(3):179.e1-179.e10. (PMID: 36577483)
Blood. 2012 Apr 5;119(14):3361-9. (PMID: 22234690)
Biol Blood Marrow Transplant. 2019 Jun;25(6):1128-1135. (PMID: 30599208)
Front Immunol. 2016 Nov 21;7:523. (PMID: 27917176)
Blood. 2010 Jun 10;115(23):4923-33. (PMID: 20203263)
Biomedicines. 2017 Jun 26;5(3):. (PMID: 28672883)
J Clin Oncol. 2002 Jan 15;20(2):405-12. (PMID: 11786567)
Blood Adv. 2019 Jun 25;3(12):1826-1836. (PMID: 31201170)
PLoS One. 2011;6(6):e21266. (PMID: 21731686)
Biol Blood Marrow Transplant. 2015 Oct;21(10):1761-9. (PMID: 26055299)
Blood Adv. 2017 Mar 28;1(9):573-576. (PMID: 29296977)
Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50. (PMID: 18489989)
Bone Marrow Transplant. 1996 Feb;17(2):243-7. (PMID: 8640174)
Blood. 2010 Jan 7;115(1):107-21. (PMID: 19887673)
Immunology. 2010 Feb;129(2):147-53. (PMID: 19922424)
Biol Blood Marrow Transplant. 2019 Oct;25(10):1984-1992. (PMID: 31212080)
Biol Blood Marrow Transplant. 2012 Sep;18(9):1422-9. (PMID: 22446014)
J Hematol Oncol. 2016 Sep 17;9(1):89. (PMID: 27639553)
Transplantation. 2003 Jul 27;76(2):297-305. (PMID: 12883182)
Blood. 2009 Oct 1;114(14):3101-12. (PMID: 19602708)
J Exp Med. 1987 Jun 1;165(6):1552-64. (PMID: 3108446)
Science. 1995 Jun 9;268(5216):1476-80. (PMID: 7539551)
J Exp Med. 2015 Jul 27;212(8):1303-21. (PMID: 26169940)
Transplant Cell Ther. 2021 Jul;27(7):601.e1-601.e7. (PMID: 33845259)
N Engl J Med. 2011 Dec 1;365(22):2055-66. (PMID: 22129252)
Leukemia. 2012 Apr;26(4):746-56. (PMID: 21926960)
Br J Haematol. 2002 Jun;117(4):935-9. (PMID: 12060133)
Biol Blood Marrow Transplant. 2016 Jul;22(7):1324-1329. (PMID: 27026249)
J Immunol. 1983 Oct;131(4):2050-8. (PMID: 6194224)
Blood. 2017 Oct 19;130(16):1857-1868. (PMID: 28835441)
Leukemia. 2013 Jul;27(7):1527-37. (PMID: 23399894)
Am J Transplant. 2018 Apr;18(4):810-820. (PMID: 28941323)
Blood. 2018 Mar 29;131(13):1399-1405. (PMID: 29437591)
Oncoimmunology. 2016 Oct 28;5(12):e1250992. (PMID: 28123892)
J Hematol Oncol. 2023 Feb 13;16(1):10. (PMID: 36782226)
N Engl J Med. 1989 Jan 26;320(4):197-204. (PMID: 2643045)
Clin Cancer Res. 2007 Oct 15;13(20):6107-14. (PMID: 17947475)
Blood. 1999 May 15;93(10):3267-75. (PMID: 10233878)
Clin Cancer Res. 2014 Apr 15;20(8):2215-25. (PMID: 24573552)
Clin Immunol. 2010 Aug;136(2):302-6. (PMID: 20452827)
Biol Blood Marrow Transplant. 2019 Dec;25(12):2338-2349. (PMID: 31415899)
Blood Adv. 2019 Sep 10;3(17):2550-2561. (PMID: 31471324)
Blood. 1977 Apr;49(4):511-33. (PMID: 14751)
Br J Haematol. 2016 Jul;174(1):102-16. (PMID: 27030315)
Bone Marrow Transplant. 2021 May;56(5):1180-1189. (PMID: 33288862)
Blood. 2009 Apr 16;113(16):3865-74. (PMID: 19168788)
Bone Marrow Transplant. 2019 Jul;54(7):1094-1106. (PMID: 30446739)
Front Oncol. 2022 Aug 09;12:895771. (PMID: 36016625)
Immunity. 2019 Nov 19;51(5):885-898.e7. (PMID: 31542340)
Lancet Haematol. 2020 Jan;7(1):e50-e60. (PMID: 31669248)
Blood. 2002 Jul 15;100(2):397-405. (PMID: 12091328)
Front Immunol. 2018 Jan 12;8:1937. (PMID: 29375566)
Front Immunol. 2020 Sep 02;11:2022. (PMID: 32983145)
Bone Marrow Transplant. 2015 May;50(5):690-5. (PMID: 25774594)
N Engl J Med. 1957 Sep 12;257(11):491-6. (PMID: 13464965)
Bone Marrow Transplant. 1994 Apr;13(4):473-7. (PMID: 8019473)
Blood. 2011 Nov 3;118(18):5011-20. (PMID: 21856864)
معلومات مُعتمدة: Z99 HL999999 United States ImNIH Intramural NIH HHS
فهرسة مساهمة: Keywords: Acute myeloid leukaemia; Allogeneic haematolpoietic stem cell transplantation; Graft-versus-host disease; Graft-versus-leukaemia
تواريخ الأحداث: Date Created: 20230623 Date Completed: 20231114 Latest Revision: 20240603
رمز التحديث: 20240603
مُعرف محوري في PubMed: PMC10291443
DOI: 10.1016/j.beha.2023.101475
PMID: 37353287
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-1924
DOI:10.1016/j.beha.2023.101475